What are the short-term effects of drug addiction? A clinician’s perspective on substance dependency
Medically reviewed by Paul Hornsey
Understanding the short-term effects of drug addiction is critical for clinicians involved in acute care, primary care, psychiatry, and addiction rehabilitation services.
These effects – ranging from cardiovascular instability and altered mental status to psychomotor impairment and behavioural dysregulation – can present rapidly and with varying severity, often mimicking or exacerbating pre-existing medical or psychiatric conditions1.
From a clinical standpoint, distinguishing between the pharmacological effects of acute intoxication, the onset of withdrawal syndromes, and underlying mental health issues is central. For example, stimulant-induced paranoia may resemble a primary psychotic episode2, while opioid-induced sedation could be mistaken for a post-ictal state3. Accurate identification is vital not only for effective triage and risk assessment, but also for tailoring intervention strategies and mitigating harm.
Moreover, short-term substance effects frequently precipitate acute psychiatric crises4, self-harm incidents, or emergency department admissions. Recognising these patterns allows clinicians to implement early interventions and to initiate discussions around long-term treatment pathways, including detoxification, harm reduction, and integrated mental health support.
Ultimately, a clear grasp of these acute presentations helps to reduce morbidity, prevent escalation, and improve outcomes for patients with substance use disorders, especially within a multidisciplinary care model.
Contact us to learn more, or make a referral today →
Central nervous system depressants
Central Nervous System (CNS) depressants – including opioids, benzodiazepines, barbiturates, and certain sedative-hypnotics – act primarily by enhancing the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)5 or, in the case of opioids, by binding to mu-opioid receptors.
Their short-term effects are clinically significant due to their rapid onset, dose-dependent impact on respiratory and cognitive function6, and high potential for synergistic toxicity when combined.
Short-term clinical effects
Withdrawal considerations
Even short-term, high-dose use can induce a withdrawal syndrome upon cessation9.
Symptoms include rebound anxiety, tremors, insomnia, tachycardia, and – especially with long-term benzodiazepine use – seizures and psychosis. These require careful tapering under medical supervision.
Clinical relevance
Clinicians must remain vigilant to the signs of acute depressant intoxication, particularly in patients presenting with altered mental status or respiratory compromise. Co-ingestion of multiple depressants significantly increases the risk of fatal overdose10. According to the UK Office for National Statistics, opioid-related deaths often involve benzodiazepines11, highlighting the need for integrated substance misuse and mental health assessment.
Central nervous system stimulants
Central Nervous System (CNS) stimulants – including substances such as cocaine, amphetamines12 (e.g. dexamphetamine, methamphetamine), methylphenidate, and synthetic cathinones – exert their effects primarily by increasing extracellular concentrations13 of dopamine, noradrenaline, and serotonin via enhanced release and reuptake inhibition.
Powerful in their effects, and sometimes used by individuals in high-demand work environments14, these agents can be associated with a distinct spectrum of short-term physiological and psychological effects that may have acute implications for clinical assessment and intervention.
Short-term clinical effects
Neurological and psychiatric:
Cardiovascular:
Gastrointestinal and other somatic:
Withdrawal and crash phase
Repeated cycles of use and withdrawal contribute to neuroadaptive changes associated with long-term cognitive and emotional dysregulation.
Stimulant withdrawal often presents as a ‘crash’ – characterised by profound fatigue, hypersomnia, dysphoria, irritability, and intense drug cravings18. While not typically life-threatening, it carries a high risk of relapse and, in some cases, suicidal ideation.
Clinical relevance
In acute presentations, stimulant intoxication should prompt careful evaluation of cardiovascular status, hydration, and mental state. Management may include benzodiazepines for agitation or seizures, and aggressive cooling for hyperthermia.
Hallucinogens and dissociatives
Hallucinogens and dissociatives constitute a diverse group of psychoactive substances that exert profound alterations in perception, mood, and cognition19.
While historically associated with recreational or illicit use, there is a growing body of clinical research20 exploring their controlled therapeutic potential in treating conditions such as depression, PTSD, and substance use disorders. Agents such as psilocybin and ketamine are currently being studied – and in some cases prescribed21 – under carefully controlled protocols for their rapid-acting antidepressant and neuroplasticity-promoting effects.
Despite this emerging evidence, unsupervised or non-clinical use of these compounds carries significant risks, particularly in acute settings. It’s important to note that this research is still in its infancy and, though showing early promise, no firm conclusions can be drawn yet.
Short-term clinical effects
Psychological and perceptual:
Neurological and somatic:
Autonomic and cardiovascular:
Complications and acute risks
Clinical relevance
While ongoing trials suggest potential for these substances in neuropsychiatric care, acute presentations in emergency or general practice settings continue to warrant careful assessment and management. Clinicians should be alert to the possibility of hallucinogen or dissociative intoxication in patients presenting with sudden onset perceptual abnormalities, unexplained agitation, or altered sensorium.
Initial treatment remains supportive, often requiring environmental de-escalation, IV fluids, and benzodiazepines in cases of severe anxiety or agitation. A clear distinction must be drawn between medically supervised psychedelic therapy and unregulated use – the latter of which can result in serious physical and psychological complications.
Cannabis and synthetic cannabinoids
Cannabis is one of the most commonly used psychoactive substances in the UK – 7.4% of adults between 16- to 59-years-old reported using cannabis within the last year27 – with increasing social acceptability and ongoing debates around its therapeutic use28.
The primary psychoactive component, Δ⁹-tetrahydrocannabinol (THC), acts on the endocannabinoid system, particularly CB₁ receptors in the central nervous system29.
Synthetic cannabinoids (e.g., “Spice,” “K2”), though structurally different, often bind with higher affinity to the same receptors30 and can elicit more potent and unpredictable effects.
Short-term clinical effects
Cognitive and psychological:
Somatic and neurological:
Respiratory:
Synthetic cannabinoids:
Marked variability:
Neuropsychiatric risk:
Clinical considerations
While low-to-moderate THC cannabis use may result in mild or self-limiting symptoms, the increasing THC:CBD ratio in modern strains poses heightened psychiatric risks. The potential for triggering or exacerbating schizophrenia-spectrum disorders34 in genetically susceptible individuals remains a key concern, particularly among adolescent users.
Synthetic cannabinoids, due to their potency and lack of regulation, represent a significant clinical challenge. Patients may present with symptoms that mimic stimulant toxicity, psychosis, or seizure disorders, necessitating careful differential diagnosis.
Initial management for both cannabis and synthetic cannabinoid intoxication is primarily supportive:
Inhalants and volatile substances
Inhalants and volatile substances refer to a diverse group of chemicals that produce psychoactive effects when their vapours are inhaled35.
Common agents include solvents (e.g., toluene, acetone), aerosols, nitrites (“poppers”), and gases such as butane or nitrous oxide. These substances are typically inhaled for their rapid onset of euphoria or disinhibition, often by younger individuals36 (although not exclusively37), or those with limited access to other drugs.
Short-term clinical effects
CNS and neuropsychiatric:
Cardiovascular:
Respiratory:
Other systemic effects:
Clinical considerations
Diagnosis of acute inhalant intoxication relies heavily on clinical suspicion – especially as these substances are often used covertly, and are undetectable via standard toxicology screens.
Presentation can mimic alcohol or sedative intoxication, but with a much shorter duration and distinctive chemical odour on the breath or clothing. Key clinical priorities include:
- Airway management and oxygenation.
- Cardiac monitoring, given the high risk of ventricular arrhythmias.
- Observation for neurotoxicity, especially in adolescents with repeated use, where long-term cognitive sequelae have been documented.
Withdrawal effects vs short-term intoxication
Clinicians must distinguish between the immediate effects of drug intoxication and the often-overlapping, yet mechanistically distinct, symptoms of withdrawal. While intoxication reflects the pharmacodynamic actions of the substance on the central nervous system (CNS), withdrawal represents the neuroadaptive rebound once that substance is removed or reduced42, particularly after sustained use.
Short-term intoxication
Short-term intoxication is characterised by a substance-specific enhancement or suppression of CNS activity. For example:
These effects are generally dose-dependent and resolve as the drug is metabolised, though toxicity or overdose may result in life-threatening complications requiring urgent medical intervention.
Withdrawal effects
In contrast, withdrawal symptoms reflect compensatory physiological responses:
Clinically, withdrawal symptoms often emerge 6–24 hours after cessation (depending on the substance’s half-life), peak within 48–72 hours, and may last several days.
Clinical red flags: when to intervene
Clinicians must distinguish between the immediate effects of drug intoxication and the often-overlapping, yet mechanistically distinct, symptoms of withdrawal. While intoxication reflects the pharmacodynamic actions of the substance on the central nervous system (CNS), withdrawal represents the neuroadaptive rebound once that substance is removed or reduced42, particularly after sustained use.
In these cases, urgent medical stabilisation, psychiatric evaluation, and referral to specialist addiction services are warranted. In all scenarios, documentation and a clear discharge plan – preferably with psychosocial follow-ups – are essential to reducing the likelihood of recurrence or harm.
Applying clinical insight to early intervention
Understanding the short-term effects of drug addiction is more than academic; it’s a clinical imperative. These early physiological and psychological signs, whether intoxication or withdrawal-related, offer valuable diagnostic windows through which healthcare professionals can identify substance use disorders at an earlier stage.
Recognising the nuanced presentation of substance use or misuse allows for:
Importantly, differentiating acute intoxication from withdrawal can guide appropriate pharmacological and psychosocial responses, prevent avoidable complications, and reduce the risk of progression to severe substance use disorder.
With many patients presenting through emergency, primary, or mental health care channels, clinicians can play a critical role in flagging high-risk cases43 and initiating conversations about substance use in a non-judgmental, evidence-informed manner.
Know someone who may be affected? Make a referral to Harbor London today →
